Stock DNA
Pharmaceuticals & Biotechnology
CNY 11,936 Million (Large Cap)
18.00
NA
2.86%
-0.34
15.93%
2.86
Revenue and Profits:
Net Sales:
670 Million
(Quarterly Results - Sep 2025)
Net Profit:
188 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.36%
0%
-6.36%
6 Months
-9.74%
0%
-9.74%
1 Year
20.02%
0%
20.02%
2 Years
10.85%
0%
10.85%
3 Years
-12.5%
0%
-12.5%
4 Years
-4.67%
0%
-4.67%
5 Years
-12.26%
0%
-12.26%
Anhui Anke Biotechnology (Group) Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.81%
EBIT Growth (5y)
15.51%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
0.68
Tax Ratio
10.50%
Dividend Payout Ratio
57.82%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
31.01%
ROE (avg)
18.43%
Valuation key factors
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
2.94
EV to EBIT
15.47
EV to EBITDA
13.06
EV to Capital Employed
3.69
EV to Sales
4.22
PEG Ratio
NA
Dividend Yield
2.92%
ROCE (Latest)
23.86%
ROE (Latest)
16.56%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
670.40
663.40
1.06%
Operating Profit (PBDIT) excl Other Income
209.20
203.70
2.70%
Interest
0.50
0.60
-16.67%
Exceptional Items
2.80
-0.00
Consolidate Net Profit
188.10
161.20
16.69%
Operating Profit Margin (Excl OI)
312.10%
259.70%
5.24%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 1.06% vs 5.50% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 16.69% vs -24.43% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,523.70
2,851.00
-11.48%
Operating Profit (PBDIT) excl Other Income
863.00
1,008.50
-14.43%
Interest
3.50
2.90
20.69%
Exceptional Items
11.40
-12.00
195.00%
Consolidate Net Profit
715.80
858.60
-16.63%
Operating Profit Margin (Excl OI)
292.70%
317.60%
-2.49%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -11.48% vs 22.93% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -16.63% vs 16.39% in Dec 2023
About Anhui Anke Biotechnology (Group) Co., Ltd. 
Anhui Anke Biotechnology (Group) Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






